[Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].
Acute promyelocytic leukemia (APL) is a special subtype of acute myeloid leukemia (AML) with M3 morphology and specific chromosomal translocation t(15;17) with resultant leukemogenic PML-RARalpha fusion gene. Its main characteristics are therapy response using all-trans-retinoic acid (ATRA) and its high rate of recovery; higher than other subtypes of acute myeloid leukemia. Arsenic trioxide induces a high complete remission rate in patients having an APL relapse. Experience in the use of this drug is still limited in the field of Paediatrics.
Moreno Tejero
M L
ML
Hospital Universitario del Niño Jesús, Madrid, España. maluped2@hotmail.com
Lassaletta Atienza
A
A
García Salido
A
A
Sevilla Navarro
J
J
Madero López
L
L
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D010087:Oxides / Q000627:therapeutic use*; D012008:Recurrence
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide